Moreover, expression of both total and phosphorylated FAK in PDA carcinoma cells is well established in the literature (7, 48–50), and a recent study by Jiang and colleagues demonstrates that targeting FAK in PDA not only augments immunotherapy efficacy, but also decreases the number of single PDA cells observed in the periductal space (7). This evidence concerns the gene PTK2 and Patent ductus arteriosus.